We did get real news on Monday but it didn't come from Clinuvel. Clinuvel had two potential competitors for EPP treatment that many believed were less than 2-3 years away from being approved. Both Bitopertin (Disc) and Dersimelagon (Tanabe) Phase II & Phase III trials failed in the past few months. Both may choose to start over or they may abandon their hopes to one day treat EPP patients altogether. Clinuvel has a monopoly on EPP treatment for many years to come. That is news by itself.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$11.65 |
Change
-0.190(1.60%) |
Mkt cap ! $593.4M | |||
| Open | High | Low | Value | Volume |
| $11.84 | $11.97 | $11.64 | $457.9K | 38.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 129 | $11.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.66 | 207 | 10 |
View Market Depth
| Last trade - 10.37am 18/09/2025 (20 minute delay) ? |
| CUV (ASX) Chart |